Breaking News Instant updates and real-time market news.

RAD

Rite Aid

$0.81

-0.0374 (-4.40%)

, MCK

McKesson

$110.67

1.48 (1.36%)

16:19
12/19/18
12/19
16:19
12/19/18
16:19

Rite Aid, McKesson agree to terms for pharmaceutical purchasing, distribution

Rite Aid (RAD) and McKesson (MCK) announced an agreement to key terms that will continue the companies' pharmaceutical sourcing and distribution partnership for an additional 10 years. Under these terms, McKesson will continue providing Rite Aid with sourcing and direct-to-store delivery for brand and generic pharmaceutical products through March 2029.

RAD

Rite Aid

$0.81

-0.0374 (-4.40%)

MCK

McKesson

$110.67

1.48 (1.36%)

  • 19

    Dec

RAD Rite Aid
$0.81

-0.0374 (-4.40%)

09/28/18
LOOP
09/28/18
NO CHANGE
Target $1.35
LOOP
Hold
Rite Aid price target lowered to $1.35 at Loop Capital on Albertsons deal
Loop Capital analyst Andrew Wolf lowered his price target on Rite Aid to $1.35 from $1.75 and kept his Hold rating after its Q2 results, saying that while the Pharmacy Services segment showed improved sales profitability, this was offset by lower profitability in Retail Pharmacy. The analyst added that the discount on the Rite Aid stock relative to the broader pharmacy group is "appropriate" given its "high debt leverage and subscale operations". Wolf further notes that the board's caving to shareholder pressure to cancel the Albertsons deal was a mistake directly linked to the 28% decline in the stock price since August 8th.
10/12/18
RHCO
10/12/18
NO CHANGE
Target $75
RHCO
Hold
Walgreens Boots Alliance price target raised to $75 from $66 at SunTrust
SunTrust analyst David MacDonald raised his price target on Walgreens Boots Alliance (WBA) to $75 after its Q4 earnings beat and FY19 guidance yesterday. The analyst says the results were marked by "solid U.S. pharmacy performance" in spite of the ongoing reimbursement and generic headwinds. MacDonald also keeps his Hold rating, adding that while the company's cash flow remains "robust" and the integration of Rite Aid (RAD) is still on track, he is concerned about the challenging environment and ongoing degradation in gross margins.
11/19/18
JEFF
11/19/18
NO CHANGE
JEFF
Jefferies uncovers signs of Amazon expanding prescription drug presence
Jefferies analyst Brian Tanquilut says his proprietary checks of Amazon.com's (AMZN) moves in the pharmacy space indicate that the online retailer has finally made moves to expand PillPack. However, the initial expansion phase appears focused on offering pharmacy services to Amazon employees in Washington. In his most recent webscrape, Tanquilut came across a new prescription license in WA, two pending Rx licenses in New Mexico and Indiana, and pharmacy technician and packaging/shipping job postings all linked to PillPack's Phoenix facility. These new developments signal the beginning of Amazon's prescription expansion via PillPack, Tanquilut tells investors in a research note. If Amazon were to rollout a more extensive PillPack offering to its own employee base, Rite Aid (RAD) could be most exposed to potential script transfers with Walgreens Boots Alliance (WBA) the least exposed among the public drugstores, says the analyst. He still believes that the impact of Amazon's pharmacy entry will take a while to materialize for drug stores CVS Health (CVS) and Walgreens.
12/14/18
GSCO
12/14/18
DOWNGRADE
Target $68
GSCO
Sell
Goldman downgrades Walgreens to Sell with $68 target, sees downside in 2019
Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance (WBA) to Sell from Neutral and lowered his price target for the shares to $68 from $73. The analyst says he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." Jones sees limited "core" growth for the large-cap names amid persisting sales and margin pressures and as drug pricing remains a regulatory focus. He downgrades Walgreens to Sell saying challenges in its retail pharmacy business "have intensified, forcing the company to search for other avenues of growth." Jones also keeps a Neutral rating on CVS Health (CVS) and Sell rating on Rite Aid (RAD).
MCK McKesson
$110.67

1.48 (1.36%)

07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
McKesson downgraded to Neutral from Outperform at Baird
07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
Express Scripts, AmerisourceBergen, McKesson cut to Neutral at Baird
As previously reported, Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC) and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against PBMs and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment, stating that visibility has deteriorated further across the supply chain.
07/20/18
07/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Philip Morris (PM) downgraded to Neutral from Overweight at JPMorgan and to Market Perform from Outperform at Cowen. 2. Skechers (SKX) downgraded to Neutral from Positive at Susquehanna and to Market Perform from Outperform at Wells Fargo. 3. McKesson (MCK), AmerisourceBergen (ABC), and Express Scripts (ESRX) downgraded to Neutral from Outperform at Baird. 4. Five Below (FIVE) downgraded to Neutral from Outperform at Credit Suisse with analyst Judah Frommer saying he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. 5. Yum China (YUMC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Chen Luo saying he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.

TODAY'S FREE FLY STORIES

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

PCG

PG&E

$7.41

0.71 (10.60%)

15:06
11/17/19
11/17
15:06
11/17/19
15:06
Hot Stocks
PG&E monitoring potential weather event that could lead to power shutoffs »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XRX

Xerox

$38.95

0.295 (0.76%)

, HPQ

HP Inc.

$20.17

0.05 (0.25%)

15:04
11/17/19
11/17
15:04
11/17/19
15:04
Hot Stocks
HP unanimously rejects unsolicited Xerox proposal »

HP Inc. (HPQ) announced…

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

FOX

Fox Corp.

$33.60

0.14 (0.42%)

, FOXA

Fox Corp.

$34.26

0.04 (0.12%)

14:49
11/17/19
11/17
14:49
11/17/19
14:49
On The Fly
Box Office Battle: 'Ford v Ferrari' races to top, 'Charlie's Angels' disappoints »

"Box Office Battle" is…

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

LGF.A

Lionsgate

$9.67

0.315 (3.37%)

LGF.B

Lionsgate

$9.07

0.345 (3.96%)

SNE

Sony

$62.03

0.23 (0.37%)

VIA

Viacom

$26.59

1.28 (5.06%)

VIAB

Viacom

$23.07

0.59 (2.62%)

T.CA

TELUS Corp. (Toronto)

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$144.63

-2.56 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

13:36
11/17/19
11/17
13:36
11/17/19
13:36
Periodicals
J&J rushed to test baby powder and got complicated results, WSJ says »

In October, Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

BA

Boeing

$371.55

4.25 (1.16%)

13:24
11/17/19
11/17
13:24
11/17/19
13:24
Periodicals
Boeing 737 makes emergency landing after engine malfunction, NY Post says »

A Canada-bound flight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17
Hot Stocks
Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding »

New results from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11
Hot Stocks
Analysis shows Jardiance decreased risk of hospitalization for heart failure »

A new interim analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09
Hot Stocks
AstraZeneca says data shows Farxiga reduces risks in heart failure patients »

AstraZeneca announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

BA

Boeing

$371.55

4.25 (1.16%)

13:05
11/17/19
11/17
13:05
11/17/19
13:05
Hot Stocks
Boeing, Biman announce order for two 787-9 Dreamliner jets »

Boeing and Biman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03
Hot Stocks
BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10 »

BridgeBio Pharma (BBIO)…

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01
Hot Stocks
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial »

Caladrius Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$6.52

0.1 (1.56%)

12:59
11/17/19
11/17
12:59
11/17/19
12:59
Hot Stocks
Kiniksa presents Rilonacept final Phase 2 clinical data »

Kiniksa Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

12:57
11/17/19
11/17
12:57
11/17/19
12:57
Hot Stocks
The Medicines Co's ORION-10 study of Inclisiran met primary, secondary endpoints »

The Medicines Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

12:54
11/17/19
11/17
12:54
11/17/19
12:54
Hot Stocks
Amgen analysis shows benefit of Repatha in high risk patients »

Amgen announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CNI

Canadian National

$93.64

0.46 (0.49%)

12:52
11/17/19
11/17
12:52
11/17/19
12:52
Hot Stocks
Canadian National receives strike notice from train conductor union »

CN said that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 22

    Nov

ADAP

Adaptimmune

$0.71

-0.0959 (-11.87%)

12:51
11/17/19
11/17
12:51
11/17/19
12:51
Hot Stocks
Adaptimmune data confirms ADP-A2M4 delivers clinical benefit »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$110.02

-0.01 (-0.01%)

, BMY

Bristol-Myers

$58.61

0.11 (0.19%)

12:47
11/17/19
11/17
12:47
11/17/19
12:47
Hot Stocks
Bristol-Myers sees no further extension for Celgene notes due to merger closing »

Bristol-Myers Squibb…

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

ETNB

89bio

$26.03

3.03 (13.17%)

, YAYO

YayYo

$3.65

-0.29 (-7.36%)

11:09
11/17/19
11/17
11:09
11/17/19
11:09
On The Fly
Opening Day: 89bio has strong opening week »

89bio (ETNB) finished its…

ETNB

89bio

$26.03

3.03 (13.17%)

YAYO

YayYo

$3.65

-0.29 (-7.36%)

CAN

Canaan

$0.00

(0.00%)

SITM

SiTime

$0.00

(0.00%)

BABA

Alibaba

$185.44

2.75 (1.51%)

YXR

YX Asset Recovery

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.